Claims for Patent: 8,932,715

Summary for Patent: 8,932,715

Title:	Precipitation stabilising compositions comprising bioactive molecule and at least one cationic and one anionic precipitation stabilizing additives
Abstract:	The present invention relates to maintaining bioactive molecules in their native or substantially near-native form and preventing or reduce aggregation. In particular, the present invention relates to precipitation-protective or stabilizing additives and a method of using said precipitation-protective/stabilizing additives to protect and maintain the bioactive molecules in a native or substantially near-native form and to prevent or reduce aggregation during or following precipitation to form particles.
Inventor(s):	Moore; Barry Douglas (Glasgow, GB), Vos; Jan (Glasgow, GB), Partridge; Johann (Glasgow, GB)
Assignee:	University of Strathclyde (GB)
Application Number:	12/597,300
Patent Claims:	1. A suspension of particles in a polar organic solvent comprising less than 25% water, wherein the particles comprise at least one bioactive molecule, wherein the particles have been prepared by precipitation of said bioactive molecule(s) from an aqueous composition comprising said bioactive molecule(s) and at least one cationic and at least one anionic precipitation stabilizing additives-, upon mixing with a greater than 3-fold excess of a polar organic solvent, wherein the resulting precipitated particles further comprise said precipitation stabilizing additive(s); wherein said bioactive molecule(s) is an aggregation-sensitive biomolecule(s); and wherein the percentage of said bioactive molecules exhibiting a changed aggregation state from the aggregation state present prior to precipitation of said particles is less than 5%. 2. The suspension according to claim 1 which is substantially free from any polymeric excipients. 3. The suspension according to claim 1 wherein the bioactive molecule is a protein with molecular mass greater than 10 kDa. 4. The suspension according to claim 1 wherein the bioactive molecule is present in the range 20%-85% w/w. 5. The suspension according to claim 1 wherein the bioactive molecule is an antibody, antibody fragment, or antibody conjugate. 6. The suspension of claim 5, wherein the antibody, antibody fragment, or antibody conjugate is a human antibody, a humanized antibody, or a fragment or conjugate of a human or humanized antibody. 7. The suspension of claim 1, wherein the aggregation-sensitive biomolecule(s) are is selected from the group consisting of granulocyte-colony stimulating factor (GCSF), stem cell factor, leptin, hematopoietic factors, non-human growth factors, antiobesity factors, trophic factors, anti-inflammatory factors, enzymes, insulin, gastrin, prolactin, adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), motilin, interferons (alpha, beta, gamma, omega), interleukins (IL-1 to IL-12), tumor necrosis factor (TNF), tumor necrosis factor-binding protein (TNF-bp), brain derived neurotrophic factor (BDNF), glial derived neurotrophic factor (GDNF), neurotrophic factor 3 (NT3), fibroblast growth factors (FGF), neurotrophic growth factor (NGF), bone growth factors, insulin-like growth factors (IGFs), macrophage colony stimulating factor (M-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), megakaryocyte derived growth factor (MGDF), keratinocyte growth factor (KGF), erythropoietin, thrombopoietin, platelet-derived growth factor (PGDF), colony simulating growth factors (CSFs), bone morphogenetic protein (BMP), superoxide dismutase (SOD), urokinase, streptokinase, and kallikrein. 8. The suspension of claim 1, wherein the aggregation-sensitive biomolecule(s) are selected from the group consisting of AVASTIN.RTM. (bevacizumab), BEXXAR.RTM. (Tositumomab), CAMPATH.RTM. (Alemtuzumab), ERBITUX.RTM. (Cetuximab), HUMIRA.RTM. (Adalimumab), RAPTIVA.RTM. (efalizumab), REMICADE.RTM. (InfliximabREOPRO.RTM. (Abciximab), SIMULECT.RTM. (Basiliximab), SYNAGIS.RTM. (Palivizumab), XOLAIR.RTM. (Omalizumab), ZENAPAX.RTM. (Daclizumab), ZEVALIN.RTM. (Ibritumomab Tiuxetan), and MYLOTARG.RTM. (gemtuzamab ozogamicin). 9. The suspension of claim 1, wherein the aggregation-sensitive biomolecule(s) are selected from the group consisting of therapeutic or diagnostic proteins and peptides; therapeutic or diagnostic nucleic acids and derivatives thereof; carbohydrates; plasmids; viruses; viral-like particles; antigens; and combination thereof. 10. The suspension of claim 1, wherein the aggregation-sensitive biomolecules show turbidity readings of less than 20 Nephelometric Turbidity Units immediately following precipitation from a polar organic solvent. 11. The suspension of claim 1, wherein the polar organic solvent is selected from the group consisting of isopropanol, isobutanol, and mixtures thereof. 12. The suspension of claim 1, wherein the particles are isolated and dried to provide dry particles that may be reconstituted in aqueous solvent to produce solutions in which the percentage of bioactive molecules exhibiting a changed aggregation state from the aggregation state present prior to precipitation of said particles is less than 5%. 13. The suspension according to claim 1, wherein the particles retain at least 95% of the bioactive molecule content following precipitation. 14. The suspension according to claim 13 wherein the particles retain at least 95% of the bioactive molecule content following storage in a sealed vial at 40.degree. C. for at least 13 weeks. 15. The suspension according to claim 1 wherein the particles have a median diameter of less than 100 .mu.m. 16. The suspension according to claim 15 wherein the particles have a median diameter of less than 10 .mu.m. 17. The suspension of claim 1, wherein the at least one anionic precipitation stabilizing additive(s) is selected from the group consisting of amino acids with an acidic side chain, N-protected amino acids with polar non-ionizable side chains, polyol acids, and sugar acids. 18. The suspension of claim 1, wherein the at least one cationic precipitation stabilising additive(s) is selected from the group consisting of amino acids with a basic side chain, C-protected amino-acids with polar non-ionizable side chains, amino polyols and amino sugars. 19. The suspension of claim 1, wherein the cationic precipitation stabilising additive is a basic precipitation stabilising additive. 20. The suspension according to claim 19 wherein the at least one basic precipitation stabilising additive(s) is selected from: amino acids with a basic side chain, C-protected amino-acids with polar non-ionisable side chains, amino polyols and amino sugars. 21. The suspension 20 wherein the basic additive is at a concentration of 1 mg/ml to 35 mg/ml in the aqueous composition. 22. The suspension according to claim 1 further comprising a neutral non-polymeric additive selected from: neutral amino acids with polar non-ionisable side chains, polyols, sugars, disaccharides and trisaccharides. 23. The suspension of claim 22, wherein the neutral precipitation stabilizing additive(s) is selected from the group consisting of polyols, monosaccharides, disaccharides and trisaccharides. 24. The suspension according to claim 22 wherein the neutral additive is at a concentration of 1 mg/ml to 50 mg/ml of the aqueous composition. 25. The suspension according to claim 1 wherein the aqueous composition further comprises a core forming coprecipitant. 26. The suspension according to claim 25 wherein the coprecipitant is present in the aqueous composition at a concentration less than its solubility limit and in the range 5 mg/ml to 200 mg/ml. 27. The suspension according to claim 25 wherein the coprecipitant has a pH in the pH range of 4-9. 28. The suspension according to claim 27 wherein the coprecipitant is alanine, asparagine, glutamine, glycine, histidine, mannitol, myoinositol, taurine, trehalose or valine. 29. The suspension according to claim 25 wherein the bioactive molecule is present in the range 0.1% w/w to 50% w/w. 30. The suspension according to claim 29, wherein the particles comprise a core made from the coprecipitant coated with the bioactive molecule and the anionic and cationic precipitation stabilizing additives.

Details for Patent 8,932,715

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2027-04-25
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2027-04-25
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2027-04-25
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2027-04-25